Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
15% lidocaine/5 mg/ml 0.02% estradiol compound cream
(Synonym: LIDOCAINE PATCH)		2件: Estradiol,
Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)		3件: D00105 ,
D00358 (Name: LIDOCAINE PATCH),
D08127 		7件: ESR1,
ESR2,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		13件: Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬1件: 226
2Alkalinized Lidocaine-Heparin
(Synonym: LIDOCAINE PATCH)		2件: Heparin,
Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)		3件: D00358 (Name: LIDOCAINE PATCH),
D07510 ,
D08127 		6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226
3All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
4ALS patients genetic characterization----1件: 2
5ANA001XHCl (Syntagon) or VEXA-04 (Patheon)----1件: 156
6Asthma patients----1件: 299
7Belimumab in SLE patients / Rituximab in RA patients2件: Belimumab,
Rituximab		2件: D02994 ,
D03068 		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
8BIIL 284 BS, high dose, adult patients----1件: 299
9BIIL 284 BS, high dose, pediatric patients----1件: 299
10BIIL 284 BS, low dose, adult patients----1件: 299
11BIIL 284 BS, low dose, pediatric patients----1件: 299
12BIIL 284 BS, medium dose, adult patients----1件: 299
13BIIL 284 BS, medium dose, pediatric patients----1件: 299
14Bladder instillation with heparin/ lidocaine
(Synonym: LIDOCAINE PATCH)		2件: Heparin,
Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)		3件: D00358 (Name: LIDOCAINE PATCH),
D07510 ,
D08127 		6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226
15Buprenorphine Transdermal Patch1件: Buprenorphine1件: D07132 2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
16Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.1件: Colchicine1件: D00570 9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 266
17Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients----1件: 2
18CF patients with a G551D mutation and treated with Ivacaftor1件: Ivacaftor1件: D09916 1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
19Cryopreserved EFS-ADA LV transduced patient CD34+ cells----1件: 65
20Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells----1件: 65
21Dietary Supplement for PKU patients----1件: 240
22EF1aS-ADA lentiviral vector transduced patient CD34+ cells----1件: 65
23ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients)1件: Myelin basic protein---1件: 13
24Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector----1件: 65
25Ex-vivo approach concerning 25 patients----2件: 102, 299
26Exelon 4.6 mg/24 h transdermal patch1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
27Exelon 9.5 mg/24 h transdermal patch1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
28Exelon Patch1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
29Exelon Patch (rivastigmine transdermal system)1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
30Exelon path transdermal1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
31Fentanyl transdermal patch1件: Fentanyl (Synonym: Ran-fentanyl Matrix Patch)1件: D00320 1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
32Gamma-secretase/Notch signalling pathway inhibitor RO4929097----1件: 74
33Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg1件: Golimumab1件: D04358 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97
34Growth hormone replacement therapy in growth hormone deficient patients only.1件: Somatotropin---1件: 78
35Heparin & Alkalinized Lidocaine Bladder Instillation
(Synonym: LIDOCAINE PATCH)		2件: Heparin,
Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)		3件: D00358 (Name: LIDOCAINE PATCH),
D07510 ,
D08127 		6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226
36HP-3000 (ropinirole hydrochloride patch)1件: Ropinirole1件: D08489 3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
37HP-3000(ropinirole hydrochloride patch)1件: Ropinirole1件: D08489 3件: DRD2,
DRD3,
DRD4 💬		8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
38In-vitro approach concerning 25 patients----2件: 102, 299
39Intervention for incipient patients at low risk of disease progression----1件: 66
40Intervention for patients at high risk of disease progression----1件: 66
41Lidocaine
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬12件: 6, 13, 22, 34, 46, 51, 70, 86, 107, 168, 226, 256
42Lidocaine 1% Injectable Solution
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 34
43Lidocaine 2% without vessel constrictor
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 51
44Lidocaine Hydrochloride, Injectable
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 70
45Lidocaine Injection 2%
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 168
46Lidocaine patch 5%1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 13
47Lidocaine Releasing Intravesical System - LiRIS®
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 226
48Local Anesthesia (lidocaine hydrochloride)
(Synonym: LIDOCAINE PATCH)		1件: Lidocaine (Synonym: Curist Lidocaine Patch Maximum Strength)2件: D00358 (Name: LIDOCAINE PATCH),
D08127 		5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 6
49Long term follow up in all patients who received SAR422459 in previous study TDU13583----1件: 301
50Loxoprofen sodium hydrogel patch1件: Loxoprofen1件: D08149 2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 271
51Neupro 2 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
52Neupro 2mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
53Neupro 2mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
54Neupro 4 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
55Neupro 4mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
56Neupro 4mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
57Neupro 4Mg/24Hr Transdermal Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
58Neupro 6 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
59Neupro 6mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
60Neupro 6mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
61Neupro 8 mg/24 h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
62Neupro 8mg/24h transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
63Nicotine patch1件: Nicotine (Synonym: Nicoderm Trd 36mg Nicotine/7 Sqcm Patch)1件: D03365 16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬		8件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬2件: 6, 84
64Nicotine transdermal patch1件: Nicotine (Synonym: Nicoderm Trd 36mg Nicotine/7 Sqcm Patch)1件: D03365 16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬		8件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬1件: 6
65Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag		4件: D00106 ,
D02721 ,
D09994 ,
D10135 		3件: EDNRA,
EDNRB,
PTGIR 💬		10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
66PAT----1件: 160
67PAT-001, 0.1%----1件: 160
68PAT-001, 0.2%----1件: 160
69Patient Current Care----1件: 46
70Patient treated with DMARD----1件: 46
71Patients will be randomized to receive EHP-101----1件: 51
72Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses----1件: 46
73PD patients H&Y=1.5-2 Medications OFF----1件: 6
74PD patients H&Y=1.5-2 Medications ON----1件: 6
75PD patients H&Y=3 Medications OFF----1件: 6
76PD patients H&Y=3 Medications ON----1件: 6
77PKD Patients----1件: 6
78Rituximab, observational study amon patients with active RA1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
79Rivastigmin Luye Transdermal Patches - 4.6mg/24h----1件: 6
80Rivastigmine Luye Transdermal Patch- 9.5mg/24h1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
81Rivastigmine Patch 9.5 cm21件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
82Rivastigmine transdermal patch1件: Rivastigmine (Synonym: Exelon Patch 5)1件: D03822 1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬2件: 6, 13
83Rotigotine transdermal patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
84Rotigotine transdermal patch 2mg/24h(10cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
85Rotigotine transdermal patch 4mg/24h (20cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
86Rotigotine transdermal patch 6mg/24h (30cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
87Rotigotine transdermal patch 8mg/24h (40cm2)1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
88Routine transdermal oestrogen patch----1件: 78
89The effectiveness of Xeljanz in rheumatoid arthritis patients1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
90TNF-blockers suspension in patients with rheumatoid arthritis----1件: 46
91Top down treatment if patient at high risk----2件: 96, 97
92Transduced patient CD34+ cells----1件: 65
93Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: D00355 2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98